TRANSGENE Announces Presentation Of Data On TG1050 Immunotherapy Against Chronic Hepatitis B And Provides Update On Its Joint Venture With Tasly Pharmaceutical In China

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) today announced that it was invited to present existing preclinical data on its proprietary program against chronic hepatitis B, TG1050 immunotherapy, at the BIT 5th Annual International Symposium of Hepatitis in Dalian, China. The presentation, entitled, “TG1050, A Novel Viral-based Immunotherapeutic Targeting Chronic Hepatitis B Infection” was given by Dr. Ren Zhu, Senior Scientist and Head of the HBV Program at TRANSGENE Biopharmaceutical Technology (Shanghai) Co., Ltd, a Transgene subsidiary located in Shanghai, China.

Help employers find you! Check out all the jobs and post your resume.